"Overall, the QIAstat-Dx Gastrointestinal Panel 2 improves pathogen detection and provides rapid, comprehensive diagnostic information, while a combined approach with conventional methods may represent the most appropriate strategy for optimizing patient management."

"QIAstat-Dx can detect all tested potentially zoonotic influenza A virus strains, and discriminate them from human sesonal influenza A viruses, ensuring a correct diagnosis. Any tool available for surveillance and pandemic preparedness is essential for a rapid response to reduce healthcare costs and severity of future influenza pandemics."

"The integration of mNGS into routine diagnostic workflows could significantly improve the diagnostic yield for viral meningoencephalitis, especially in cases with negative or inconclusive results from traditional methods. However, further studies are necessary to refine its clinical application, optimize cost-effectiveness, and establish guidelines for its use in the diagnostic management of meningoencephalitis."

"This study highlights the benefits of using multiplex PCR panels, such as the QIAstat-Dx Gastrointestinal Panel (QGP), which provides results for 23 pathogens simultaneously within 80 min. This extensive retrospective study evaluated the performance of QGP in 4,801 stool samples collected in a pediatric tertiary care center in Qatar. The QGP showed superior diagnostic performance compared with traditional methods, including enhanced pathogen detection and faster results, helping clinicians optimize the treatment of children with gastroenteritis."

"In conclusion, PCR Ct values, when interpreted together with comorbidity burden, may be a useful tool for predicting severe CDI and may contribute to clinical decision-making."

"Meningitis can colonize synovial tissue through hematogenous dissemination of the germ, leading to septic arthritis. Although a specific and early diagnosis is necessary, management based on early and appropriate antibiotic therapy. This work opens up the prospect of a larger-scale study enabling long-term follow-up of patients affected by meningitis, in order to improve our knowledge of its localization."

"The results of our study indicate that the use of NAAT assays as standalone tests for diagnosing CDI in children can be enhanced by using Ct-based reporting. Furthermore, our study suggests that a PCR Ct-based report combined with clinical presentation and risk factor assessment may help reduce unnecessary antibiotic use for CDI without compromising patient safety. Since the accuracy of molecular testing results may vary depending on the PCR assay used and the C. difficile prevalence in specific populations, PCR Ct values for CDI diagnosis should be validated in each particular setting."

"This case underscores the value of syndromic PCR diagnostics, rapid intervention, and vigilant environmental surveillance in neonatal infection control. National and international water safety plans must maintain surveillance and infection prevention measures to prevent severe neonatal Legionella pneumonia."

"CSF Ct values can assist in risk stratification for timely ICU admission in individuals with CAM."

"Overall, the QIAstat provided clinically significant additive data to antimicrobial susceptibility predictions in our isolate cohort. Implementation of the QIAstat will require clear standard operating procedures that include decision support for the bench technologist and antimicrobial steward on how to interpret results in the context of the genus detected. These protocols will be best informed by local epidemiology, as this may differ from ours."

"The results of our study suggest that NAAT assays can be used as standalone tests followed by the assessment of PCR Ct value for positive samples to diagnose CDI more accurately and differentiate colonization from infection in children. As results may vary based on the method and the C. difficile prevalence in each patient population, laboratories considering this approach will need to validate the use of PCR Ct values for CDI diagnosis in their own setting. In addition, the reporting of the toxin production alongside the PCR results reduced the overtreatment of colonized children."

The QIAstat-Dx® GIP2 demonstrates high diagnostic accuracy compared to the Allplex™ GI, BIOFIRE® GI, and Xpert® Norovirus assays. With an overall 95.02% PPA and 99.98% PNA, the GIP2 proved exceptionally reliable for bacterial and parasitic targets, showing lower CT values than the Allplex™ assays. Despite a slightly lower viral sensitivity of 88.3%, the GIP2 remains a robust tool for rapid syndromic testing from Fecalswab® specimens.

"Overall, the QIAstat-Dx GIP 2 assay is comparable to the commercially available nucleic acid amplification assays [Cepheid Xpert C. difficile, BD MAX Cdiff, Verigene CDF, and BioFire GI panel] for the detection of C. difficile, and the rapid assay setup time offers an efficient laboratory testing workflow."

"The use of M-PCR in microbiology laboratories for the early detection and treatment of ME does not exempt culture and subsequent analyses by conventional methods. M-PCR panels, although they have a high cost, offer important advantages, such as a faster turn-around time, which can impact the management of the patient. The QIAstat-Dx ME is easy to use and has a fast turnaround time, and it shows a higher sensitivity and specificity (96.43% and 95.24%, respectively) as well as positive-predictive and negative-predictive values (96.43% and 95.24%, respectively). In addition, the results obtained are accompanied by an amplification curve and its corresponding Ct value, which allows for a better microbiological interpretation together with other clinical data. Conversely, while the Filmarray ME demonstrated high sensitivity (85.1%), it also yielded some false positives, yielding a low PPV of 71.8%. The additional performance of routine tests may be beneficial, especially in cases in which the diagnosis remains uncertain."

"In conclusion, the QGP [QIAGEN QIAstat-Dx gastrointestinal panel] performed well for the molecular diagnosis of gastroenteritis with excellent PPA and NPA against the BGP [bioMerieux BioFire FilmArray gastrointestinal panel] in our pediatric population. The Ct value provided by the QGP also offers a potential advantage over the BGP and could be helpful in estimating the relative abundance of each pathogen in positive samples. However, further clinical studies of the QGP Ct values would be required to understand their additional value in the diagnosis and management of gastroenteritis."

This multicenter study compared the diagnostic performance of the QIAstat-Dx Respiratory Panel 2.0 and the BioFire Respiratory Panel 2.1 using 269 clinical specimens. The results showed an overall agreement of 86.3% between the two devices. While both systems demonstrated high specificity, the BioFire-RP2.1 exhibited superior analytical sensitivity, particularly in cases with low viral loads or co-detections involving pathogens like adenovirus, RSV, and SARS-CoV-2. Conversely, the QIAstat-Dx-RP2.0 was noted for its practical advantages, including better handling, lower noise, and the ability to provide semi-quantitative data.

"The overall specificity of all three platforms was comparable; however, the sensitivity of the QRP [QIAstat-Dx® Respiratory SARS-CoV-2 Panel] was inferior to that of the ARV and FARP [FilmArray® Respiratory 2.1 plus Panel]."

"The rising benefits of the combined use of POC biomarkers with molecular diagnostics [FILMARRAY and QIAstat-Dx RP] in daily clinical routine appear to outperform conventional practices in terms of reduced turnaround time, timely diagnosis, and prompt administration of the appropriate treatment. Yet, this must be further demonstrated in future investigations. However, the cost-effectiveness of POC tests and the high rate of false positive and negative results, indicate the need for a comprehensive clinical evaluation."

"Both panels [QIAstat-Dx RP, BioFire RP2plus against the Alere™ i] can be valuable tools for clinicians, since they both display high sensitivity and specificity. We report a slightly better performance for BioFire RP2plus, since it produced no invalid results."

"In summary, the QIAstat-Dx ME Panel exhibited similar performance relative to the comparator method - the BioFire FilmArray ME Panel - in this clinical trial study involving three testing sites in Europe. The results obtained in this clinical performance study contribute to the body of evidence demonstrating the scientific validity of multiplex PCR panels in detecting and identifying bacterial, viral, and fungal pathogens to aid in diagnosing specific causative agents of meningitis and/or encephalitis, in conjunction with SoC techniques, such as culture for organism recovery, serotyping, genotyping, and antimicrobial susceptibility testing. Ultimately, multiplex PCR will likely replace some SoC methods, and the QIAstat-Dx ME Panel offers a valuable new alternative for multiplex PCR testing for ME. While the QIAstat-Dx ME Panel is a qualitative assay, it is unique in that - unlike the BioFire FilmArray ME Panel - it also provides information on Ct values for its targets, which reflects a sample’s pathogenic load; this information may be useful in guiding physicians on patient management and adds a layer of data that might help interpret results in the laboratory. Featuring a robust and accurate assay, the panel facilitates rapid and comprehensive testing for community-acquired meningoencephalitis."

Monitoring SARS-CoV-2 genetic variability: A post-market surveillance workflow for combined bioinformatic and laboratory evaluation of commercial RT-PCR assay performance.

The QIAstat-Dx ME Panel is a highly effective syndromic assay with a diagnostic agreement (PPA) generally above 90%, performing comparably to the BioFire FilmArray. Its primary advantage is the provision of Ct values and amplification curves, offering better interpretative depth for clinicians. Despite its reliability, the panel shows target-specific weaknesses, particularly with HSV-1 and HHV-6 false negatives. While a valuable tool for rapid CNS infection screening, its clinical utility for low-prevalence targets like M. pneumoniae is still unproven, and it should complement rather than replace traditional diagnostic workflows.

"The multiplex gastrointestinal pathogen panel test is a simpler and faster test than traditional microbiology methods. However, the effect of these test results on the patient`s diagnosis and treatment needs to be investigated. More studies are needed to compare standard and molecular methods."

"In conclusion, our multicenter assessment of the QIAstat-Dx Gastrointestinal Panel 2 revealed that this testing system displayed high PPA and NPA in detecting 17 targets of bacterial, viral, and parasitic origin. The system allows reporting of Ct values, which might provide additional research insights on the infection status and be of particular interest in the context of co-infections. QIAstat-Dx Gastrointestinal Panel 2 provides a new alternative for multiplex gastrointestinal testing that, with its accurate and robust assay, allows for the rapid and comprehensive testing of gastrointestinal infections."

"Multiparametric molecular panels are a valuable tool for the rapid and accurate diagnosis of meningitis and encephalitis. Compared to traditional diagnostic methods, such as culture and quantitative molecular tests, they offer several advantages, including the simultaneous detection of multiple pathogens and a reduced TAT. However, they have certain limitations, including the lack of information on antimicrobial susceptibility in bacterial infections, the exclusion of some potential CNS pathogens (e.g., Toscana virus and West Nile virus), and lower sensitivity (approximately 90%) compared to singleplex PCR. Furthermore, they do not provide quantitative data (copies/mL). In our study, the QIA/ME demonstrated an overall sensitivity of 85.9% for detecting viral infections. When singleplex PCR results exceeded 250 copies/mL for DNA viruses and 500 copies/mL for the RNA virus, the concordance rate with QIA/ME was 96.8%. Additionally, we observed a strong correlation (ρ = −0.83, p < 0.001) between Ct values and viral load, providing valuable insights."

"The QS-ME is a relevant addition to the syndromic testing landscape to assist in diagnosing infectious ME."

"In conclusion, the diagnosis of CDI in children remains a challenge due to the high rate of colonization in children and lack of consensus regarding gold standards. Our study showed variability in test performance of the different available assays in diagnosing CDI. An algorithm starting with sensitive XCD or QGP as a screening test followed by a specific toxin assay for positive samples using the CDQ showed the best performance in our population when combined with clinical review of the patient symptoms, alternative diagnoses, and risk factors for CDI. To further improve the diagnostic efficiency of C. difficile testing, health care facilities should implement strict criteria to ensure testing is only performed on pediatric patients with a higher pre-test probability of having CDI."

The evaluation of the QIAstat-Dx BCID GN and GPF kits demonstrates high diagnostic accuracy for identifying pathogens and predicting antimicrobial resistance directly from positive blood culture bottles. The kits showed exceptional sensitivity and specificity for beta-lactam resistance in Enterobacterales and Staphylococci, notably through the detection of ctx-m, ampC, blaZ, and mecA genes.While the prediction of resistance for non-$\beta$-lactam antibiotics was more variable, these rapid multiplex PCR panels significantly reduce the turnaround time for actionable clinical data. When integrated with antimicrobial stewardship, they enable earlier optimization of therapy for bacteremia, though traditional culture methods remain necessary to account for non-targeted resistance mechanisms and local epidemiology.

The QIAstat-Dx Respiratory SARS-CoV-2 Panel (RS2P) demonstrated strong diagnostic performance in this comprehensive evaluation, achieving an overall consensus agreement of 99.6%. Despite a few initial technical failures, the system proved highly reliable for the simultaneous detection of 21 viral and bacterial targets in both upper and lower respiratory specimens. By providing rapid results and CT values, the panel serves as an effective tool for optimizing patient care and antimicrobial stewardship during respiratory infection seasons.

The QIAstat-Dx Gastrointestinal Panel (Q-GP) demonstrates high diagnostic accuracy, with over 90% agreement across most major pathogens when compared to the Luminex xTAG (L-GPP). While clinical performance is nearly identical, the QIAstat-Dx offers a significant operational advantage by reducing hands-on preparation to 5 minutes and delivering results in under 1.5 hours. This efficiency supports faster clinical decision-making and better antimicrobial stewardship, making it a highly effective tool for rapid syndromic testing in acute gastroenteritis.